Valentis is a Wash
This post is a month later than it should have been – anyone following the stock of Valentis (VLTS) knows that on July 11, 2006 Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. The stock tanked 90% on the news and later, the company announced it would cut staffing by 60%. When I recommended the stock, I had mentioned the risk involved (as is true of all biotechs – specially microcaps). This one was a wash and if you still own it, you should sell it before it gets delisted on the Nasdaq and hits the pink sheets.
– Faisal Laljee
